alexa Quantitation of Insulin Analogue Glargine and Its Two M
ISSN: 2155-9872

Journal of Analytical & Bioanalytical Techniques
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Quantitation of Insulin Analogue Glargine and Its Two Metabolites M1 and M2 on Triple Quad 6500 and Triple TOF 5600 LC-MS/MS Systems in a Dog Toxicokinetics Study

Yong-Xi Li1*, Yan Ke1, Junyu Li1, Yu Li2, Run Li2, Xiaofeng Chen2, Sahana Mollah3 and Xu Wang3

1Medpace, Bioanalytical Laboratories, Cincinnati, Ohio, USA

2HEC Pharma Co. Ltd, 5th Industrial Area Shangsha, China

3AB SCIEX, Framingham, Massachusetts, USA

*Corresponding Author:
Yong-Xi Li
Medpace, Bioanalytical Laboratories, 5365 Medpace Way
Cincinnati, Ohio, 45227, USA
Tel: +1-513-579-9911 ext 2070
Fax: +1-513-579-0444
E-mail: [email protected]

Received date: November 15, 2013; Accepted date: December 18, 2013; Published date: December 20, 2013

Citation: Li YX, Ke Y, Li J, Li Y, Li R, et al. (2013) Quantitation of Insulin Analogue Glargine and Its Two Metabolites M1 and M2 on Triple Quad 6500 and Triple TOF 5600 LC-MS/MS Systems in a Dog Toxicokinetics Study. J Anal Bioanal Tech S5: 004. doi: 10.4172/2155-9872.S5-004

Copyright: © 2013 Li YX, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Glargine is a long lasting bioengineered insulin analogue commonly used in the medical treatment of insulindependent diabetes mellitus. After subcutaneous injection, glargine undergoes enzymatic process generating two metabolites, M1 and M2. Quantitative evidences of their presence and concentration after doping multiple concentrations are important for clinical study. Such information can also help to understand the pharmacokinetics, pharmacodynamics, and toxicology during the insulin drug development. We developed and validated a high throughput analytical method coupled with solid-phase extraction (SPE) and LC-MS/MS for the quantitation of intact insulin in plasma samples for use in pre-clinical and clinical studies. The multiple-reaction-monitoring (MRM) experiments performed on a triple-quadruple mass spectrometry instrument were used for quantitation. A 3.5 min UHPLC method was developed to achieve high throughput. An eight-point standard calibration curve with concentration from 0.2 ng/mL to 20 ng/mL was constructed corresponding to the normal non-fasting insulin levels in plasma. The acceptance criteria for values of accuracy, precision, and linearity of the quantitation curve were developed in accordance to the bioanalytical method validation guidance published by Food and Drug Administration (FDA) and European Medicines Agency (EMA). This validated MRM method was applied for toxicity study of insulin analogues in dog. The toxicokinetic results were reported. Moreover, we compared the MRM results to the MS quantitation results acquired on a hybrid quadruple-quadruple time-of-flight (QqTOF) and showed the high resolution instrument can be an option for peptide and biotherapeutic protein quantitation.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version